MES Maintains Chain of Identity

With Cell/Gene Therapy, the treatment must be provided ‘vein to vein’ in a limited period of time—with the same rigorous controls as any other biologic. This manufacturer, not unlike others in this industry, also had additional process challenges to accommodate cell count variations in the starting material. In addition, this customer’s autologous process requires maintaining strict chain of identity across the supply chain with no room for error.

In Cell/Gene Therapy, the uniqueness of each batch requires it to be adjusted for every patient’s starting material. That’s where MES comes in: MES maintains control over a complex manual process; MES automatically tracks materials usage to an individual patient lot and maintains identity of the lot; and MES recipes help accommodate varied growth timelines for varying starting material.